Abbott Laboratories Inc. has agreed to acquire St. Jude Medical Inc. for $25 billion, creating a third player – along with Boston Scientific Corp. and Medtronic PLC – that competes in all major sectors of the cardiovascular device business.
During the April 28 earnings call announcing the definitive merger agreement, Abbott Chairman and CEO Miles White emphasized the firms' complementary cardiovascular product portfolios, covering almost every part of the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?